BUY Piramal Pharma Limited — Rakesh Bansal
byRakesh BansalHorizon: Swing (≤2wk)30 Jul 2026via Zee Business (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·3 Aug · yesterday
3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·30 Jul · 5d ago
Q1 Results Highlights: Piramal Pharma Loss Narrows; Eicher Motors Profit Jumps Over 21%; Waaree Energies Revenue Soars 79%
NewsNdtv-Profit·29 Jul · 6d ago
Piramal Pharma Q1 Results: Net Loss Narrows As Margin Expands; Revenue Up 17%
NewsNdtv-Profit·29 Jul · 6d ago
Piramal Pharma Limited announced its Q1 FY27 financial results, reporting a 17% increase in revenue from operations and a 72% rise in EBITDA. The company highlighted strong performance across all thre
NSE · Press Release·29 Jul · 6d ago
Buy, Sell Or Hold: Mahindra & Mahindra, UltraTech Cement, Piramal Pharma, Groww And Swiggy — Ask Profit
NewsNdtv-Profit·30 Jul · 5d ago
Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·29 Jul · 6d ago
Piramal Pharma temporarily suspends Ahmedabad plant operations due to heavy rainfall
NewsCnbc-Tv18·25 Jul · 2w ago
Piramal Pharma, Authum Investment, Vaibhav Global Show Technical Breakouts
NewsGoogle News·20 Jul · 2w ago
HDFC Mutual Fund reduces stake in Piramal Pharma by 2.005%
NewsGoogle News·18 Jul · 2w ago
HDFC Mutual Fund Sells 2% Stake in Piramal Pharma
NewsGoogle News·17 Jul · 3w ago
HDFC Mutual Fund ने Piramal Pharma मधील हिस्सा विकला, मोठी घट!
NewsGoogle News·17 Jul · 3w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.